Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL254969 | 0.83 | ALDH1A1 (0.56) | KMT2AMEN1CES2CES1RAB9A | |
| SCHEMBL27711150 | 0.82 | KMT2A (0.51) | KMT2AMEN1CES2CES1RAB9A | |
| SCHEMBL254968 | 0.80 | MEN1 (0.61) | KMT2AMEN1CES2CES1RAB9A | |
| SCHEMBL15343524 | 0.79 | KMT2A (0.67) | KMT2AMEN1TP53ALDH1A1ADRA1D | |
| SCHEMBL474163 | 0.79 | ADRA1D (0.48) | KMT2AMEN1RAB9ATP53NPC1 | |
| SCHEMBL15218738 | 0.79 | CES2 (0.53) | KMT2ACES2CES1RIPK1 | |
| SCHEMBL15265666 | 0.78 | MAPT (0.48) | KMT2AMEN1TP53MAPTSMN1; SMN2 | |
| SCHEMBL3628079 | 0.78 | KDM4E (0.53) | KMT2AMEN1TP53MAPTGAA | |
| SCHEMBL3454955 | 0.77 | TP53 (0.67) | KMT2AMEN1CES2CES1RAB9A | |
| SCHEMBL12086331 | 0.77 | MEN1 (0.46) | KMT2AMEN1CES2CES1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | disclosed |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-09-05 | — | — | US | disclosed |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012154194-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | FORMA TM, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012150952-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031199-A1 | GUANIDINE COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | KMT2A 659/4885MEN1 438/4885CES2 1322/4885 |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | KMT2A 1299/4885MEN1 468/4885CES2 1189/4885 |
| US-20130295051-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KMT2A 1563/4885MEN1 537/4885CES2 683/4885 |
| US-10472342-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | KMT2A 4666/4885MEN1 4044/4885CES2 54/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | KMT2A 908/4885MEN1 473/4885CES2 598/4885 |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | KMT2A 4666/4885MEN1 4044/4885CES2 54/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | KMT2A 4741/4885MEN1 4365/4885CES2 84/4885 |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | KMT2A 1299/4885MEN1 468/4885CES2 1189/4885 |
| US-10457655-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | KMT2A 4666/4885MEN1 4044/4885CES2 54/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KMT2A 1615/4885MEN1 582/4885CES2 693/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KMT2A 1615/4885MEN1 582/4885CES2 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.